Login to Your Account



Diamyd Shares Surge on $625M Diabetes Deal with J&J Unit

By Cormac Sheridan


Wednesday, June 23, 2010
Shares in Diamyd Therapeutics AB surged by around 30 percent Tuesday on news of a potential $625 million partnering deal with Ortho-McNeil-Janssen Pharmaceuticals (OMJP) Inc., involving its Phase III therapeutic vaccine for Type I diabetes, which is also called Diamyd. The Stockholm, Sweden-based company is getting $45 million up front and could earn up to $580 million more in development and commercial milestones. It would also receive tiered royalties on product sales. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription